ReviewMolecules (Basel, Switzerland)2026
Medicine-Food Homology Bioactives for Polyendocrine Metabolic Ovarian Syndrome: Multi-Target Mechanisms and Functional Food Translation.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is characterized by insulin resistance, hyperandrogenism, chronic inflammation, and oxidative stress, with a global prevalence of 10-13% and limited current drug treatments. Medicine-Food Homology (MFH) materials are rich in bioactive compounds such as polyphenols, flavonoids, and polysaccharides, offering potential multi-target nutritional interventions for PMOS, although safety data remain limited mainly to single compounds. A systematic search of the literature was conducted across PubMed/MEDLINE, Web of Science CNKI, and Wanfang Data, spanning from database inception to August 2026, utilizing predefined search terms and inclusion/exclusion criteria. This review summarizes research on MFH-derived bioactive compounds in PMOS, covering active component identification, network pharmacology-based target prediction, key signaling pathways (PI3K/AKT, AMPK, NF-κB, Nrf2/HO-1), and formulation strategies including green extraction, nano-encapsulation, and controlled release. It further discusses functional food development from five perspectives: meal replacement powders, functional teas, fermented beverages, dietary supplements, and compound formulations. Key bottlenecks hindering commercialization are analyzed, including insufficient high-quality clinical evidence, unclear dose-response relationships, and limited long-term stability data. Future directions are proposed, such as organoids, organ-on-a-chip, AI-driven formulation optimization, and international multicenter trials. In summary, MFH bioactive compounds show potential as multi-target interventions for PMOS; however, most mechanistic evidence comes from non-PMOS metabolic models, and direct PMOS-specific evidence is limited. Their translation from empirical use to evidence-based intervention requires PMOS-specific preclinical validation, randomized controlled trials, safety assessments, bioavailability evaluation, and standardized product validation, alongside collaborative efforts across research paradigms, technology development, and industrial translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.